Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients With Any Cancer With Bone Metastases Other Than Breast Cancer, Multiple Myeloma or Prostate Cancer
NCT00003884 is registered in ClinicalTrials.gov with Novartis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients With Any Cancer With Bone Metastases Other Than Breast Cancer, Multiple Myeloma or Prostate Cancer
- Lead sponsor
- Novartis
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 1998
- Completion date
- January 31, 2001
- Enrollment
- 600 (estimated)
- Sites
- 55
Conditions
As the registry lists them; a condition with its own page is linked.
hypercalcemia of malignancy, lung cancer, metastatic cancer, pain, unspecified adult solid tumor, protocol specific